Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of “Moderate Buy” by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $18.00.

EPRX has been the subject of several research reports. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Oppenheimer assumed coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an “outperform” rating and a $17.00 price target on the stock.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new stake in Eupraxia Pharmaceuticals in the third quarter valued at $7,965,000. Affinity Asset Advisors LLC grew its position in shares of Eupraxia Pharmaceuticals by 429.7% during the first quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after acquiring an additional 1,289,005 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the 2nd quarter worth about $6,851,000. Seven Fleet Capital Management LP bought a new stake in Eupraxia Pharmaceuticals in the 1st quarter valued at about $5,137,000. Finally, Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals during the 1st quarter valued at about $5,068,000.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $7.50 on Friday. The stock’s 50 day simple moving average is $6.64 and its 200 day simple moving average is $6.99. Eupraxia Pharmaceuticals has a 12-month low of $5.15 and a 12-month high of $9.32. The firm has a market cap of $487.65 million, a P/E ratio of -7.35 and a beta of 1.07. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. As a group, equities research analysts predict that Eupraxia Pharmaceuticals will post -0.87 EPS for the current year.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.